Forum

Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.

Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).

Forum Update: Supporting Community-Led Discussion

The forum was created as a space for shared learning and peer support, and as the community grows, we want to lean more fully into that purpose.

Going forward, PAAB will be taking a more listening-first role in forum discussions. Rather than responding immediately to every question, we’ll be encouraging members to engage with one another, share experiences, and help build collective understanding. PAAB will continue to monitor conversations and will step in to:

Correct any misunderstandings
Provide guidance when questions remain unanswered after a few days
Support discussions where official clarification is needed

Our goal is to foster a collaborative, trusted community where knowledge is shared and strengthened by everyone’s contributions.

Thank you for being part of the conversation.

Guidance Documents for Claims Based on Kaplan-Meier Analysis

Guidance on Code Application

1 Posts 1 Posters 6.4k Views 2 Watching

D Offline
D Offline
devadmin

wrote on last edited by Jennifer Carroll

#1

Enter your comments on these documents here:

Please note that provisions 1, 2, 4, 5, 7 and 8 are effective immediately.

Provisions 3 and 6 will be implemented beginning April 2021.
1 Reply Last reply

0

The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.